3 completed, 2 terminated. 3 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow gusperimus: new trials by email Literature Review of gusperimus trials Research Report on gusperimus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids - Wegeners Granulomatosis | Phase 3 | Terminated | Nordic Pharma SAS | 4 | 2011-11-01 | 2015-05-29 |
| Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection Deoxyspergualin - Chronic Rejection | Not applicable | Terminated | Nippon Kayaku Co., Ltd. | 35 | 2009-06-01 | 2014-01-08 |
| Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin - Diabetes Mellitus, Type 1 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 14 | 2006-10-01 | 2016-03-16 |
| Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis Gusperimus - Wegener's Granulomatosis | Phase 2 | Completed | Nippon Kayaku Co., Ltd. | 45 | 2003-12-01 | 2017-03-06 |
| Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis NKT-01 - Lupus Nephritis | Phase 1 / Phase 2 | Completed | Nippon Kayaku Co., Ltd. | 21 | 2003-10-01 | 2017-01-10 |
Granulomatosis with Polyangiitis (2) · Diabetes Mellitus, Type 1 (1) · Hypoglycemia (1) · Lupus Nephritis (1) · Recurrence (1) · Vasculitis (1)
Nippon Kayaku Co., Ltd. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nordic Pharma SAS (1)
Czechia (3) · Germany (2) · Denmark (1) · Japan (1) · Netherlands (1) · Sweden (1) · United Kingdom (1) · United States (1)
Andrew Posselt, MD, PhD (1) · Bernhard Hering, MD (1) · David Jayne (1) · David Jayne, MD (1) · Hanns-Martin Lorenz, Professor (1) · Hiroshi Harada, Chief (1) · Xunrong Luo, MD, PhD (1)